ArticleInternational journal of environmental research and public health2017
Determinants of Quality of Life in High-Dose Benzodiazepine Misusers.
Article in International journal of environmental research and public health, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Effective alleviation of depressive and anxious symptoms and sleep disorders in benzodiazepine-dependent patients through repetitive transcranial magnetic stimulation.Addiction biology · 2024Trial
- Benzodiazepine Use and Mortality Risk: A Nationwide Cohort Study on New Benzodiazepine Users With a 5-Year Follow-Up.Acta psychiatrica Scandinavica · 2026Article
- Evoked craving in high-dose benzodiazepine users.Frontiers in psychiatry · 2025Article
- UK Medical Cannabis Registry: Assessment of clinical outcomes in patients with insomnia.Brain and behavior · 2024Article
- High-dose benzodiazepine use and QTc interval prolongation, a latent class analysis study.Scientific reports · 2024Article
- Benzodiazepine use, quality of life and psychiatric symptom burden in oral and injectable opioid agonist treatment: a cross-sectional study.Addiction science & clinical practice · 2023Article
- Long-term use of benzodiazepines in chronic insomnia: a European perspective.Frontiers in psychiatry · 2023Article
- Study protocol-Evoked craving in high-dose benzodiazepine users.Frontiers in psychiatry · 2022Article
- Polysubstance Use Patterns Among High Dose Benzodiazepine Users: A Latent Class Analysis and Differences Between Male and Female Use.Frontiers in psychiatry · 2022Article
- Benzodiazepines in sport, an underestimated problem: Recommendations for sports medicine physicians' practice.Frontiers in psychiatry · 2022Article
- Benzodiazepine high-doses: The need for an accurate definition.International journal of methods in psychiatric research · 2021Review
- Continuous Infusion of Flumazenil in the Management of Benzodiazepines Detoxification.Frontiers in psychiatry · 2021Article
- High-Dose Dependence and Cognitive Side Effects to Medical Prescription of Etizolam.Frontiers in psychiatry · 2020Article
- Detoxification Improves Multidomain Cognitive Dysfunction in High-Dose Benzodiazepine Abusers.Frontiers in neuroscience · 2020Article
- Beyond Prescriptions Monitoring Programs: The Importance of Having the Conversation about Benzodiazepine Use.Journal of clinical medicine · 2019Article
- Changes in Prescription of Psychotropic Drugs After Introduction of Polypharmacy Reduction Policy in Japan Based on a Large-Scale Claims Database.Clinical drug investigation · 2019Observational
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Benzodiazepines (BZDs) are among the most widely prescribed drugs in developed countries, but they have a high potential for tolerance, dependence and misuse. High-dose BZD misuse represents an emerging addiction phenomenon, but data on quality of life (QoL) in high-dose BZD misusers are scant. This study aimed to explore QoL in high-dose BZD misuse. We recruited 267 high-dose BZD misusers, compared the QoL scores in those who took BZD only to poly-drug misusers, and explored the role of demographic and clinical covariates through multivariable analysis. Our data confirmed worse QoL in high-dose BZD misusers and showed that (a) QoL scores were not negatively influenced by the misuse of alcohol or other drugs, or by coexisting psychiatric disorders; (b) demographic variables turned out to be the most significant predictors of QoL scores; (c) BZD intake significantly and negatively influenced QoL. Physical and psychological dimensions of QoL are significantly lower in high-dose BZD misusers with no significant effect of comorbidities. Our data suggest that the main reason for poor QoL in these patients is high-dose BZD intake per se. QoL should be considered among outcome measures in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.